NGNE · Neurogene Inc.

Neurogene Inc. announced first quarter 2026 financial results alongside significant clinical progress for its lead program NGN-401 in Rett syndrome. The company reported a net loss of $30.9 million, up from $22.6 million in Q1 2025, driven primarily by elevated R&D expenses of $25.2 million versus $17.8 million prior year. This increase stemmed from heightened clinical trial costs for the Embolden registrational study of NGN-401, CMC activities, and R&D headcount expansion, partially offset by reduced spending on the CLN5 Batten disease program and early discovery efforts. G&A expenses held steady at $8.2 million, reflecting offsets from lower non-cash stock-based compensation against rises in pre-commercial and employee-related costs. Balance sheet remains robust with $243.2 million in cash, cash equivalents, and short-term investments as of March 31, 2026, providing runway into Q1 2028 and supporting key milestones ahead. CEO Rachel McMinn highlighted momentum in the Embolden trial, with ~90% of participants dosed and on track for completion in Q2 2026; NGN-401 at the 1E15 vg dose has shown good tolerability with no hemophagocytic lymphohistiocytosis cases reported as of May 11, 2026. Additional updates include a presentation at ASGCT on ICV delivery advantages and leadership enhancements with Christy Shafer as CCO, bringing rare neurological disease launch expertise, and Christine Mikail joining the board for strategic and financial acumen. Investors should note anticipated catalysts: updated Phase 1/2 data with 12+ months follow-up mid-2026, PPQ start mid-2026, and ongoing commercial readiness, positioning NGN-401 toward potential approval in a high-value rare disease market.